Cohero Health has closed a seed investment round of 2 million dollars from Zaffre Investments, the investment arm of Blue Cross Blue Shield of Massachusetts; Three Leaf Ventures an affiliate of the Broe Group, Bioadvance; and Swanhill Capital. StartUp Health, of which Cohero Health is a member, also participated via their digital health syndicate on AngelList.

Cohero Health’s connected devices and mobile apps engage and empower respiratory patients by measuring lung function and tracking adherence. The company’s proprietary platform comprises wireless medication inhaler sensors to track patient adherence, an FDA cleared mobile spirometer to measure lung function, mobile apps to engage patients, generate custom reminders and reward compliance, and access to custom data via HIPAA-compliant servers to support robust patient monitoring.

Cohero Health to use the funding to scale production of its devices to support large customer deployments, and the full-scale commercial launch of its platform.Cohero Health enables tracking of controller medication, rescue medication and discern lung function in real-time; it is poised to transform care of asthma and COPD patients through improved self-management, and by empowering clinicians with critical components of optimal respiratory care, knowing how patients are using their medication and how they are responding.

“Cohero Health connects patients to care providers in an unprecedented way, allowing for the many stakeholders in the respiratory community to benefit from a tool that addresses proactive treatment compliance and mobile lung function monitoring,” said Melissa Manice, PhD, Co-Founder. “The funds raised and depth of expertise of our strategic investors allow us to ramp up manufacturing and bring us to full commercial readiness to meet current customer demand.”

Cohero Health has successfully deployed its platform at Mount Sinai Health System and Dartmouth-Hitchcock Medical Center, and plans to announce more partnerships before year’s end. Early results have shown a 2.5 times increase in medication adherence over standard of care, and 100% reduction in hospitalizations.

The company plans to use the funding to scale production of its devices to support large customer deployments, and the full-scale commercial launch of its platform.